CLYM stock news · Climb Bio, Inc.

Stories about Climb Bio, Inc. (CLYM) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CLYM

Follow Climb Bio, Inc. (CLYM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Oct 23, 2026, 5:38 PM ET · Market
Climb Bio, Inc. shares new results from its first clinical trial for CLYM116.
Good for CLYM
Climb Bio reported lasting changes in measures linked to kidney disease, with no serious safety problems in these tests. The results support CLYM116, but patient results are still pending.
Sep 8, 2026, 9:20 AM ET · Market
Robinhood might jump about 23%. Check out 10 expert predictions for Tuesday.
Good for CLYM
Climb Bio Inc saw its price target raised from $24 to $30 and the analyst kept a Buy rating, reflecting improved analyst outlook.